维普中文期刊产品整合服务
30篇 您的检索式:作者名="MAGDALENA H"
    题名 作者 年代 出处 被引量
1Procalcitonin,and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites显示文摘AIM:To quantitate the simultaneous serum and ascitic fluid levels of procalcitonin and inflammatory markers in cirrhotics with and without ascites.METHODS:A total of 88 consecutive severe cirrhotic patients seen in a large city hospital liver clinic were studied and divided into two groups,those with and without ascites.Group 1 consisted of 41 cirrhotic patients with massive ascites,as demonstrated by necessity for therapeutic large-volume paracentesis.Group 2consisted of 47 cirrhotic patients without any clinically documented ascites to include either a recent abdominal computed tomography scan or ultrasound study.Serum and ascitic fluid levels of an array of inflammatory markers,including procalcitonin,were measured and compared to each other and a normal plasma panel(NPP).RESULTS:The values for inflammatory markers assayed in the serum of Groups 1 and 2,and ascitic fluid of the Group 1.The plasma levels of the inflammatory cytokines interleukin(IL)-2,IL-4,IL-6,IL-8,interferon gamma(IFNγ)and epidermal growth factor(EGF)were all significantly greater in the serum of Group 1as compared to that of the serum obtained from the Group 2 subjects(all P<0.05).There were significantly greater serum levels of IL-6,IL-8,IL-10,monocyte chemoattractant protein-1,tumor necrosis factor-α,vascular endothelial growth factor and EGF when comparing Group 2 to the NPP.There was no significant difference for IL-1A,IL-1B,IL-2,IL-4 and IFNγlevels between these two groups.Serum procalcitonin levels were increased in cirrhotics with ascites compared to cirrhotics without ascites,but serum levels were similar to ascites levels within the ascites group.Furthermore,many of these cytokines,but not procalcitonin,demonstrate an ascites-to-serum gradient.Serum procalcitonin does not demonstrate any significant difference segregated by liver etiology in the ascites group;but ascitic fluid procalcitonin is elevated significantly in car-diac cirrhosis/miscellaneous subgroup compared to the hepatitis C virus and alcoholic cirrhosis subgroups.CONCLUSION:Procalcitonin in the ascitic fluid,but not in the serum,differentiates between cirrhotic subgroup reflecting the dynamic interplay of ascites,bacterial translocation and the peri-peritoneal cytokine.Bashar M Attar Christopher M Moore Magdalena George Nicolae Ion-Nedelcu Rafael Turbay Annamma Zachariah Guiliano Ramadori Jawed Fareed David H Van Thiel 2014World Journal of Gastroenterology2014,20,9:4
2Disease dependent qualitative and quantitative differences in the inflammatory response to ascites occurring in cirrhotics显示文摘AIM:To assess differing patterns and levels of ascitic fluid cyctokine and growth factors exist between those with a high risk and low risk of spontaneous bacterial peritonitis(SBP). METHODS: A total of 57 consecutive patients with ascites requiring a large volume paracentesis were studied. Their age, gender, specific underlying disease conditions were recorded after a review of their clinical records. Each underwent a routine assessment prior to their paracentesis consisting of a complete blood count, complete metabolic profile and prothrombin time/international normalized ratio(INR) determination. The ascitic fluid was cultured and a complete cellcount and albumin determination was obtained on the fluid. In addition, blood and ascitic fluid was assessed for the levels of interleukin interleukin(IL)-1A, IL-1B, IL-2, IL-4, IL-8, IL-10, monocyte chemotactic protein(MCP)-1, tumor necrosis factor(TNF)-α, interferon(IFN)-γ, vascular endothelial growth factor(VEGF) and epidermal growth factor(EGF) utilizing the Randox Biochip platforms(Boston, MA). A serum-ascites gradient, for each cytokine and growth factor was calculated. The results are reported as mean ± SEM between disease groups with statistical analysis consisting of the student t-test(two tailed) with a P value of 0.05 defining significance. RESULTS: No clinically important demographic or biochemical differences between the 4 groups studied were evident. In contrast, marked difference in the cytokine and growth factors levels and pattern were evident between the 4 disease groups. Individuals with alcoholic cirrhosis had the highest levels of IL-1A, IL-1B, IL-4, IFNγ. Those with malignant disease had the highest levels of IL-2. Those with hepatitis C virus(HCV) associated cirrhosis had the highest value for IL-6, IL-8, IL-10, MCP-1 and VEGF. Those with cardiac disease had the highest level of TNF-α and EGF. The calculated serum- ascites gradients for the cardiac and malignant disease groups had a greater frequency of negative values signifying greater levels of IL-8, IL-10 and MCP-1 in ascites than did those with alcohol or HCV disease. CONCLUSION: These data document important differences in the cytokine and growth factor levels in plasma, ascitic fluid and the calculated plasma- ascites fluid gradients in cirrhotics requiring a large volume paracentesis. These differences may be important in determining the risk for bacterial peritonitis.Bashar M Attar Magdalena George Nicolae Ion-Nedelcu Guilliano Ramadori David H Van Thiel 2014World Journal of Hepatology2014,6,2:3
3Androgen, progesterone, and FSH receptor polymorphisms in ovarian cancer risk and outcome 显示文摘Agnieszka H L Magdalena M Grzegorz P 2009Endocr Relat Cancer2009,16,3:1
4Involvement of the Arp2/3 complex and Scar2 in Golgi polarity in scratch wound models显示文摘MAGDALENA J MILLARD T H ETIENNE-MANNEVILLE S 2003Mol Biol Cell2003,14,2:1
5Thermal and structural behaviour of a full-scale composite building subject to a severe compartment fire显示文摘Samantha F Magdalena C Christina H 2007Fire Safety Journal2007,42,3:1
6Survey and molecular genetics of SHV β-lactamases in Enterobacteriaceae in Switzerland : Two novel enzymes, SHV-11 and SHV-12显示文摘Magdalena T N Fritz H K Herbert H 1997Antimicrob Agents Chemother1997,,5:1
7Predictivevalue of intial computerized tomography scan,Intraeranial pressure and state of autoregnlation in patients with traumatic brain injury显示文摘Magdalena H Marek C Peter H 2006J Neurosurg2006,104,5:1
8Quality of life in psy- chogenic nonepileptic seizures 显示文摘Jerzy Ps Cynthia H Magdalena S 2003Intern League Against Epilepsy2003,44,:1
9Synthesis and Amyloid Binding Properties of Rhenium Complexes: Preliminary Progress Toward a Reagent for SPECT Imaging of Alzheimer's Disease Brain显示文摘Zhen W Han H Magdalena A 1999J Med Chem1999,42,:1
10FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer显示文摘AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.METHODS This is a retrospective multicenter cohort, evaluating the efficacy and safety of the association of aflibercept with FOLFIRI3(day 1: aflibercept 4 mg/kg, folinic acid 400 mg/m^2, irinotecan 90 mg/m^2, 5-fluorouracil infusion 2400 mg/m^2 per 46 h; day 3: irinotecan 90 mg/m^2) in patients with previously treated metastatic colorectal cancer. The primary endpoint was overall response rate(ORR). Secondary endpoints were disease control rate(DCR), progression-free survival(PFS), overall survival(OS), and safety.RESULTS Among 74 patients treated in four French centers, nine were excluded due to prior use of aflibercept(n = 3), more than one prior treatment line in irinotecanna?ve patients(n = 3), and inadequate liver function(n = 3). In the 'irinotecan-na?ve' patients(n = 30), ORR was 43.3% and DCR was 76.7%. Median PFS and OS were 11.3 mo(95%CI: 6.1-29.0) and 17.0 mo(95%CI: 13.0-17.3), respectively. The most common(> 5%) grade 3-4 adverse events were diarrhea(37.9%), neutropenia(14.3%), stomatitis and anemia(10.4%), and hypertension(6.7%). In the 'pre-exposed irinotecan' patients(n = 35), 20(57.1%) received ≥ 2 prior lines of treatment. ORR was 34.3% and DCR was 60.0%. Median PFS and OS were 5.7 mo(95%CI: 3.9-10.4) and 14.3 mo(95%CI: 12.8-19.5), respectively.CONCLUSION Minimally modified FOLFIRI has improvement dramatically the FOLFIRI3-aflibercept efficacy, whatever prior use of irinotecan. A prospective randomized trial is warranted to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept.CANDice Carola Fran?ois Ghiringhelli Stefano Kim Thierry ANDré Juliette Barlet Le?la Bengrine-Lefevre Hélène Marijon Marie-Line Garcia-Larnicol Christophe Borg Linda Dainese Nils Steuer Hubert Richa Magdalena Benetkiewicz Annette K Larsen Aimery de Gramont Benoist Chibaudel 2018World Journal of Clinical Oncology2018,9,5:1
11Bradykinin B2 receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates显示文摘Dimcho R B Steeve H Magdalena B 2001J Pharm Exper Therap2001,297,1:1
12Biotechnological possibilities for waste tyre-rubber treatment显示文摘Olle H Bengt S Magdalena C 1998Biodegradation1998,9,:1
13Quality of life in psychogenic nonepileptic seizures显示文摘Jerzy PS Cynthia H Magdalena S 2003Intern League Against Epilepsy2003,44,:1
14Improving data access in P2P systems显示文摘KARL A MANFRED H MAGDALENA P 2002IEEE Internet Computing2002,6,1:1
15Pestivirus and alphaherpesvirus infections in Swedish reindeer (Rangifer tarandus tarandus L)显示文摘Arja H Kautto Stefan Alenius Magdalena Larska 0,,1:1
16Biotechnological possibilities for waste tyre-rubber treatment 显示文摘Olle H Bengt S Magdalena C 1998Biodegradation1998,9,:1
17A review of US and Canadian biomass supply studies显示文摘MAGDALENA G SATISH J MECLEAN H L 2009Bioresource2009,4,1:1
18HaLoop : efficient itera- tive data processing on large clusters 显示文摘Yingyi B Bill H Magdalena B 2010Proceedings of the VLDB Endowment2010,3,12:1
19Survey and molecular genetics of SHV β-lactamases in Enterobacteriaceae in Switzerland:two novel enzymes,SHV-11 and SHV-12显示文摘MAGDALENA T N FRITZ H K HERBERT H 1997Antimicrobial Agents and Chemotherapy1997,41,5:1
20The role of affect in the crea- tion and Intentional pursuit of entrepreneurial ideas显示文摘JAMES C H MAGDALENA C 2012Entre- preneurship Theory and Practice2012,,1:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费